First Patient With PDAC Receives ELI-002 7P in Phase 2 AMPLIFY-7p Study

TARGETED ONCOLOGY: The first patient with KRAS-mutated pancreatic ductal adenocarcinoma (PDAC) has been dosed with ELI-002 7P in the phase 2 AMPLIFY-7P study (NCT05726864), according to Elicio Therapeutics, Inc.